<DOC>
	<DOCNO>NCT02886299</DOCNO>
	<brief_summary>Sixty chronic hemodialysis patient randomly assign receive fenofibrate 100 mg ( group 1 , n = 30 ) simvastatin 20 mg ( group 2 , n = 30 ) three times/week dialysis session . The safety efficacy drug lipid profile , oxidize low density lipoprotein ( ox-LDL ) , glutathione peroxidase ( GSH-Px ) C-reactive protein ( CRP ) compare 16-week treatment .</brief_summary>
	<brief_title>Randomized Comparative Efficacy Safety Study Intermittent Simvastatin Fenofibrate Hemodialysis</brief_title>
	<detailed_description>This prospective randomize open label parallel study . The selected patient randomly allocate one two group - Group I ( 30 patient ) : Patients receive fenofibrate ( 100 mg ) take dialysis day dialysis session ( three time per week ) . - Group II ( 30 patient ) : Patients receive simvastatin ( 20 mg ) take dialysis day dialysis session ( 3 time per week ) . A careful history patient include demographic characteristic , physical examination , chief complaint , past medical history , drug history , familial history , social history , disease ( ) . Monitoring Parameters : For efficacy , follow parameter measure : 1 . Lipid profile ( total cholesterol , HDL , TG LDL Friedwald formula [ 10 ] { LDL-C= TC- [ HDL + TG\5 ] ) . ( measured baseline every month 4 month ) 2 . C-reactive protein ( CRP ) . ( measured baseline 4 month ) 3 . Oxidative stress marker : oxidize LDL human glutathione peroxidase ( measure baseline 4 month ) . For safety : ( measure baseline every month 4 month ) 1 . Observe sign &amp; symptom muscle toxicity measure phosphocreatine kinase ( CPK ) . 2 . Liver function test : ALT , AST , ALP &amp; albumin . 3 . Urea &amp; serum creatinine . ( monitor renal function ) 4 . Hemoglobin 5 . Other measurement : Body mass index ( BMI ) , Blood Pressure , electrolytes ( Sodium , potassium , calcium , phosphorous ) ass patient compliance tablet counting . Statistical analysis use compare effect simvastatin fenofibrate lipid profile , inflammatory marker ( CRP ) oxidative stress marker ( oxidize LDL glutathione peroxidase ) . In addition , compare safety renal hepatic function , phosphocreatine kinase , blood pressure blood glucose level .</detailed_description>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Chronic hemodialysis patient 3 dialysis session per week . 3 . Lipid profile : 1 . Total Cholesterol ≥ 200 mg/dl LDL ≥ 130 mg/dl . 2 . Triglycerides ≥ 150 mg/dl . 1 . Previous intolerance fibrates statin . 2 . Use fibrates statin within 6 month prior study . 3 . Hypothyroidism . 4 . Active liver disease [ unexplained persistent increase liver enzyme ( ALT &amp; AST &gt; 2x ULN ) ] . 5 . Uncontrolled hypertension . 6 . History MI coronary bypass surgery last 3 month . 7 . Muscle toxicity ( Phosphocreatine kinase ( CPK ) &gt; 2x ULN ) . 8 . Gall bladder disease . 9 . Use immunosuppressant steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Fibrates</keyword>
	<keyword>Statins</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Improved Oxidative Stress</keyword>
	<keyword>Egypt</keyword>
</DOC>